ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0921

The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort

Alexandru Garaiman1, Carina Mihai1, Rucsandra Dobrota1, Suzana Jordan1, Britta Maurer2, Jan Flemming3, Oliver Distler4 and Mike Oliver Becker1, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, 3Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland

Meeting: ACR Convergence 2020

Keywords: mental health, OMERACT, Patient reported outcomes, Psychometrics, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The Hospital Anxiety and Depression Scale (HADS) is a screening tool used in patients with different medical conditions. However, its validity, reliability and responsiveness to change in systemic sclerosis (SSc) patients have not been evaluated yet.

Our objectives were to evaluate the feasibility, validity, reliability, and responsiveness of the Hospital Anxiety and Depression Scale (HADS) and to analyse its model structure in patients with systemic sclerosis (SSc).

Methods: In this study, 307 systemic sclerosis patients were included, of these, 90 participated in the responsiveness analysis. Psychometric properties were tested in analogy to the Outcome Measures in Rheumatology (OMERACT) filter and an exploratory and confirmatory factor analysis was performed to examine the structure of HADS.

Results: The HADS showed adequate feasibility, validity, reliability, and responsiveness to clinically relevant worsening of the disease (table 1). For our population of SSc patients, the HADS model with two sub-scales, HADS-A and HADS-D, and a general scale HADS-S, measuring anxiety, depression, and distress, respectively, was most appropriate (figure 1). The rates of anxiety, depression, mixed anxiety-depressive disorder (MADD) and distress identified by HADS in our cohort were 32.7%, 26.1%, 18.6%, and 49.7%, respectively (figure 2).

Conclusion: The psychometric properties of the HADS make it useful for screening in SSc, where anxiety, depression, MADD, and distress represent a significant burden to patients.

Table 1: HADS assessed by OMERACT filter criteria

Figure 1: Exploratory Factor Analysis. Parallel analysis scree plot: the solid line shows eigenvalues of actual data, while the dotted and dashed lines (placed on top of each other) show simulated and resampled data. The point of inflection – the point where the gap between simulated data and actual data tends to be minimum – occurs at a number of factors supported by our model (n=2) (left panel); Factor analysis: item loadings of the model sub-scales (right panel).

Figure 2: Cases and rates of anxiety, depression, distress and MADD stratified by gender and SSc subset Legend: dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis


Disclosure: A. Garaiman, None; C. Mihai, Roche, 9, Geneva Romfarm, 9, Boehringer Ingelheim, 5; R. Dobrota, None; S. Jordan, None; B. Maurer, AbbVie, 2, Protagen, 2, Novartis Biomedical Research, 2, Pfizer, 9, Roche, 9, Actelion, 9; J. Flemming, None; O. Distler, Actelion, 2, 5, 8, Bayer, 2, 5, 8, Boehringer Ingelheim, 2, 5, 8, Medscape, 5, 8, Novartis, 8, Roche, 5, 8, Menarini, 8, Mepha, 8, MSD, 5, 8, iQone, 8, Pfizer, 5, 8, AbbVie, 5, Acceleron Pharma, 5, Amgen, 5, AnaMar, 5, Arxx Therapeutics, 5, Beacon Discovery, 5, Blade Therapeutics, 5, CSL Behring, 5, ChemomAb, 5, Corpus Pharma, 5, Curzion Pharmaceuticals, 5, Ergonex Pharma, 5, Mitsubishi Tanabe Pharma, 2, 5, Kymera Therapeutics, 2, 5, Catenion, 5, Galapagos NV, 5, GlaxoSmithKline, 5, Glenmark Pharmaceuticals, 5, Inventiva, 5, Italfarmaco, 5, Lilly, 5, Sanofi, 5, UCB, 5, IQVIA, 5, Medac, 5, Target BioScience, 5, Patent issued, 9; M. Becker, None.

To cite this abstract in AMA style:

Garaiman A, Mihai C, Dobrota R, Jordan S, Maurer B, Flemming J, Distler O, Becker M. The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-hospital-anxiety-and-depression-scale-in-patients-with-systemic-sclerosis-a-psychometric-and-factor-analysis-in-a-monocentric-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-hospital-anxiety-and-depression-scale-in-patients-with-systemic-sclerosis-a-psychometric-and-factor-analysis-in-a-monocentric-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology